Selected research
Industry Research
T Lymphocyte Activation Antigen CD80 Industry Research Report 2026
Market perspective
The global T Lymphocyte Activation Antigen CD80 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for T Lymphocyte Activation Antigen CD80 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for T Lymphocyte Activation Antigen CD80 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for T Lymphocyte Activation Antigen CD80 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of T Lymphocyte Activation Antigen CD80 include Mologen AG, MedImmune LLC, KAHR medical Ltd, Bristol-Myers Squibb Co, BioAtla LLC and 3SBio Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global T Lymphocyte Activation Antigen CD80 market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
T Lymphocyte Activation Antigen CD80 Market by Company
Mologen AG
MedImmune LLC
KAHR medical Ltd
Bristol-Myers Squibb Co
BioAtla LLC
3SBio Inc
T Lymphocyte Activation Antigen CD80 Segment by Type
Abatacept Biosimilar
Abatacept
KAHR-102
CUE-201
Others
T Lymphocyte Activation Antigen CD80 Segment by Application
Autoimmune Disorders
Acute Myelocytic Leukemia
Metabolic Disorders
Others
T Lymphocyte Activation Antigen CD80 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Lymphocyte Activation Antigen CD80 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of T Lymphocyte Activation Antigen CD80 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Lymphocyte Activation Antigen CD80.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of T Lymphocyte Activation Antigen CD80 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of T Lymphocyte Activation Antigen CD80 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of T Lymphocyte Activation Antigen CD80 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Abatacept Biosimilar
- Abatacept
- KAHR-102
- CUE-201
- Others
Applications
- Autoimmune Disorders
- Acute Myelocytic Leukemia
- Metabolic Disorders
- Others
Companies covered
- Mologen AG
- MedImmune LLC
- KAHR medical Ltd
- Bristol-Myers Squibb Co
- BioAtla LLC
- 3SBio Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global T Lymphocyte Activation Antigen CD80 Market Size (2021-2032)
- 2.2.2 Global T Lymphocyte Activation Antigen CD80 Sales (2021-2032)
- 2.2.3 Global T Lymphocyte Activation Antigen CD80 Market Average Price (2021-2032)
- 2.3 T Lymphocyte Activation Antigen CD80 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Abatacept Biosimilar
- 2.3.3 Abatacept
- 2.3.4 KAHR-102
- 2.3.5 CUE-201
- 2.3.6 Others
- 2.4 T Lymphocyte Activation Antigen CD80 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Autoimmune Disorders
- 2.4.3 Acute Myelocytic Leukemia
- 2.4.4 Metabolic Disorders
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global T Lymphocyte Activation Antigen CD80 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global T Lymphocyte Activation Antigen CD80 Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global T Lymphocyte Activation Antigen CD80 Revenue of Manufacturers (2021-2026)
- 3.4 Global T Lymphocyte Activation Antigen CD80 Average Price by Manufacturers (2021-2026)
- 3.5 Global T Lymphocyte Activation Antigen CD80 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of T Lymphocyte Activation Antigen CD80, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of T Lymphocyte Activation Antigen CD80, Product Type & Application
- 3.8 Global Manufacturers of T Lymphocyte Activation Antigen CD80, Established Date
- 3.9 Global T Lymphocyte Activation Antigen CD80 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Mologen AG
- 4.1.1 Mologen AG Company Information
- 4.1.2 Mologen AG Business Overview
- 4.1.3 Mologen AG T Lymphocyte Activation Antigen CD80 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Mologen AG T Lymphocyte Activation Antigen CD80 Product Portfolio
- 4.1.5 Mologen AG Recent Developments
- 4.2 MedImmune LLC
- 4.2.1 MedImmune LLC Company Information
- 4.2.2 MedImmune LLC Business Overview
- 4.2.3 MedImmune LLC T Lymphocyte Activation Antigen CD80 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 MedImmune LLC T Lymphocyte Activation Antigen CD80 Product Portfolio
- 4.2.5 MedImmune LLC Recent Developments
- 4.3 KAHR medical Ltd
- 4.3.1 KAHR medical Ltd Company Information
- 4.3.2 KAHR medical Ltd Business Overview
- 4.3.3 KAHR medical Ltd T Lymphocyte Activation Antigen CD80 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 KAHR medical Ltd T Lymphocyte Activation Antigen CD80 Product Portfolio
- 4.3.5 KAHR medical Ltd Recent Developments
- 4.4 Bristol-Myers Squibb Co
- 4.4.1 Bristol-Myers Squibb Co Company Information
- 4.4.2 Bristol-Myers Squibb Co Business Overview
- 4.4.3 Bristol-Myers Squibb Co T Lymphocyte Activation Antigen CD80 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bristol-Myers Squibb Co T Lymphocyte Activation Antigen CD80 Product Portfolio
- 4.4.5 Bristol-Myers Squibb Co Recent Developments
- 4.5 BioAtla LLC
- 4.5.1 BioAtla LLC Company Information
- 4.5.2 BioAtla LLC Business Overview
- 4.5.3 BioAtla LLC T Lymphocyte Activation Antigen CD80 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 BioAtla LLC T Lymphocyte Activation Antigen CD80 Product Portfolio
- 4.5.5 BioAtla LLC Recent Developments
- 4.6 3SBio Inc
- 4.6.1 3SBio Inc Company Information
- 4.6.2 3SBio Inc Business Overview
- 4.6.3 3SBio Inc T Lymphocyte Activation Antigen CD80 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 3SBio Inc T Lymphocyte Activation Antigen CD80 Product Portfolio
- 4.6.5 3SBio Inc Recent Developments
5 Global T Lymphocyte Activation Antigen CD80 Market Scenario by Region
- 5.1 Global T Lymphocyte Activation Antigen CD80 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global T Lymphocyte Activation Antigen CD80 Sales by Region: 2021-2032
- 5.2.1 Global T Lymphocyte Activation Antigen CD80 Sales by Region: 2021-2026
- 5.2.2 Global T Lymphocyte Activation Antigen CD80 Sales by Region: 2027-2032
- 5.3 Global T Lymphocyte Activation Antigen CD80 Revenue by Region: 2021-2032
- 5.3.1 Global T Lymphocyte Activation Antigen CD80 Revenue by Region: 2021-2026
- 5.3.2 Global T Lymphocyte Activation Antigen CD80 Revenue by Region: 2027-2032
- 5.4 North America T Lymphocyte Activation Antigen CD80 Market Facts & Figures by Country
- 5.4.1 North America T Lymphocyte Activation Antigen CD80 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America T Lymphocyte Activation Antigen CD80 Sales by Country (2021-2032)
- 5.4.3 North America T Lymphocyte Activation Antigen CD80 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe T Lymphocyte Activation Antigen CD80 Market Facts & Figures by Country
- 5.5.1 Europe T Lymphocyte Activation Antigen CD80 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe T Lymphocyte Activation Antigen CD80 Sales by Country (2021-2032)
- 5.5.3 Europe T Lymphocyte Activation Antigen CD80 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific T Lymphocyte Activation Antigen CD80 Market Facts & Figures by Country
- 5.6.1 Asia Pacific T Lymphocyte Activation Antigen CD80 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific T Lymphocyte Activation Antigen CD80 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific T Lymphocyte Activation Antigen CD80 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America T Lymphocyte Activation Antigen CD80 Market Facts & Figures by Country
- 5.7.1 South America T Lymphocyte Activation Antigen CD80 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America T Lymphocyte Activation Antigen CD80 Sales by Country (2021-2032)
- 5.7.3 South America T Lymphocyte Activation Antigen CD80 Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa T Lymphocyte Activation Antigen CD80 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa T Lymphocyte Activation Antigen CD80 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa T Lymphocyte Activation Antigen CD80 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa T Lymphocyte Activation Antigen CD80 Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global T Lymphocyte Activation Antigen CD80 Sales by Type (2021-2032)
- 6.1.1 Global T Lymphocyte Activation Antigen CD80 Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global T Lymphocyte Activation Antigen CD80 Sales Market Share by Type (2021-2032)
- 6.2 Global T Lymphocyte Activation Antigen CD80 Revenue by Type (2021-2032)
- 6.2.1 Global T Lymphocyte Activation Antigen CD80 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global T Lymphocyte Activation Antigen CD80 Revenue Market Share by Type (2021-2032)
- 6.3 Global T Lymphocyte Activation Antigen CD80 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global T Lymphocyte Activation Antigen CD80 Sales by Application (2021-2032)
- 7.1.1 Global T Lymphocyte Activation Antigen CD80 Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global T Lymphocyte Activation Antigen CD80 Sales Market Share by Application (2021-2032)
- 7.2 Global T Lymphocyte Activation Antigen CD80 Revenue by Application (2021-2032)
- 7.2.1 Global T Lymphocyte Activation Antigen CD80 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global T Lymphocyte Activation Antigen CD80 Revenue Market Share by Application (2021-2032)
- 7.3 Global T Lymphocyte Activation Antigen CD80 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 T Lymphocyte Activation Antigen CD80 Value Chain Analysis
- 8.1.1 T Lymphocyte Activation Antigen CD80 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 T Lymphocyte Activation Antigen CD80 Production Mode & Process
- 8.2 T Lymphocyte Activation Antigen CD80 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 T Lymphocyte Activation Antigen CD80 Distributors
- 8.2.3 T Lymphocyte Activation Antigen CD80 Customers
9 Global T Lymphocyte Activation Antigen CD80 Analyzing Market Dynamics
- 9.1 T Lymphocyte Activation Antigen CD80 Industry Trends
- 9.2 T Lymphocyte Activation Antigen CD80 Industry Drivers
- 9.3 T Lymphocyte Activation Antigen CD80 Industry Opportunities and Challenges
- 9.4 T Lymphocyte Activation Antigen CD80 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst